To determine whether continuing anti-ezrin treatment after tumor resection had any further effect on reducing metastasis, we next evaluated the efficacy of NSC in a neoadjuvant plus adjuvant treatment model, as detailed in Fig. 7A. The gene discussed is EZR; the disease is neoplasm.